Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 8936 results

  1. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    In development Reference number: GID-TA11130 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Asunercept for treating glioblastoma [ID1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  4. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    In development Reference number: GID-TA11869 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Deuruxolitinib for treating severe alopecia areata [ID6597]

    In development Reference number: GID-TA11804 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  7. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]

    Awaiting development Reference number: GID-TA11325 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain

    Awaiting development Reference number: GID-HTG10168 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  10. Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]

    Awaiting development Reference number: GID-TA11703 Expected publication date:  25 February 2026

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    Awaiting development Reference number: GID-TA11624 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTE10079 Expected publication date:  27 January 2027

    Health technology evaluations
    In development

  13. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    Awaiting development

  14. In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death

    In development Reference number: GID-IPG10405 Expected publication date:  19 November 2026

    Interventional procedures guidance
    In development

  15. Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]

    Awaiting development Reference number: GID-TA11950 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development